Andrey Zaritskey

3.6k total citations
66 papers, 1.0k citations indexed

About

Andrey Zaritskey is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Andrey Zaritskey has authored 66 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hematology, 35 papers in Genetics and 15 papers in Molecular Biology. Recurrent topics in Andrey Zaritskey's work include Chronic Lymphocytic Leukemia Research (27 papers), Chronic Myeloid Leukemia Treatments (25 papers) and Acute Myeloid Leukemia Research (13 papers). Andrey Zaritskey is often cited by papers focused on Chronic Lymphocytic Leukemia Research (27 papers), Chronic Myeloid Leukemia Treatments (25 papers) and Acute Myeloid Leukemia Research (13 papers). Andrey Zaritskey collaborates with scholars based in Russia, Italy and United States. Andrey Zaritskey's co-authors include Renata I. Dmitrieva, Sergey V. Anisimov, Michele Baccarani, Carlo Gambacorti‐Passerini, H. Jean Khoury, Hagop M. Kantarjian, Jörge E. Cortes, Dong‐Wook Kim, Nadine Besson and Virginia Kelly and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Andrey Zaritskey

58 papers receiving 988 citations

Peers

Countries citing papers authored by Andrey Zaritskey

Since Specialization

Citations

This map shows the geographic impact of Andrey Zaritskey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrey Zaritskey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrey Zaritskey more than expected).

Fields of papers citing papers by Andrey Zaritskey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrey Zaritskey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrey Zaritskey. The network helps show where Andrey Zaritskey may publish in the future.

Co-authorship network of co-authors of Andrey Zaritskey

This figure shows the co-authorship network connecting the top 25 collaborators of Andrey Zaritskey. A scholar is included among the top collaborators of Andrey Zaritskey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrey Zaritskey. Andrey Zaritskey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation 2023 ·Pathophysiology ·Konstantin Bogdanov, (unknown), (unknown), (unknown), Elza Lomaia, (unknown), (unknown), Andrey Zaritskey	0
2	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study 2021 ·Hematological Oncology ·Francesco Passamonti, Vikas Gupta, Bruno Martino, Lynda Foltz, Andrey Zaritskey, Haifa Kathrin Al‐Ali, Renato Tavares Daher, Margherita Maffioli, Pia Raanani, Pilar Giraldo, Martin Grießhammer, Paola Guglielmelli, (unknown), Carole Paley, Ranjan Tiwari, Alessandro M. Vannucchi	8
3	CAR T-Cell Therapy with NKG2D Chimeric Antigen Receptor in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome 2021 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), Andrey Zaritskey, Alexey Petukhov	0
4	Identification of Mutations in IDH1/2, DNMT3A, ASXL1 Genes of Genome Epigenetic Regulation and Their Co-Occurrence with FLT3, NPM1, RUNX1 Mutations in Acute Myeloid Leukemia 2021 ·SHILAP Revista de lepidopterología ·(unknown), Ekaterina Zaikova, Alexey Petukhov, Oleg N. Demidov, (unknown), (unknown), (unknown), (unknown), (unknown), Konstantin Bogdanov, (unknown), (unknown), Andrey Zaritskey, (unknown)	1
5	The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report 2021 ·BMC Women s Health ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Konstantin Bogdanov, (unknown), (unknown), (unknown), (unknown), Vladimir Ivanov, Alexey Petukhov, (unknown), Andrey Zaritskey	13
6	Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure 2020 ·Biology ·(unknown), (unknown), Vladimir Ivanov, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Andrey Zaritskey	3
7	Efficient Transduction of T-Lymphocytes by Lentiviral Particles in Oncoimmunological Studies 2020 ·SHILAP Revista de lepidopterología ·Ekaterina Zaikova, (unknown), (unknown), Alexandra Daks, Andrey Zaritskey, Alexey Petukhov	1
8	Gemtuzumab Ozogamicin in the Treatment of Critical Patients with Refractory Acute Myeloid Leukemia (3 Case Reports) 2020 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Konstantin Bogdanov, (unknown), (unknown), Ksenia Zagorodnikova, Nataliya Zhukova, (unknown), (unknown), (unknown), Andrey Zaritskey	0
9	Ovarian tissue cryopreservation in prepubertal patients with oncological diseases: multidisciplinary approach and outcomes 2019 ·The Journal of Maternal-Fetal & Neonatal Medicine ·(unknown), М. Б. Белогурова, Andrey Zaritskey, (unknown), В. И. Цибизова, (unknown), (unknown), (unknown)	14
10	Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study 2019 ·Leukemia ·Francesc Bosch, Guy Cantin, Agostino Cortelezzi, Wolfgang Knauf, Mourad Tiab, Mehmet Turgut, Andrey Zaritskey, (unknown), Eugen Tausch, Kerstin Trunzer, Susan Robson, Ekaterina Gresko, Sebastian Böttcher, Robin Foà, Stephan Stilgenbauer, Véronique Leblond	6
11	Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia 2018 ·Annals of Hematology ·Владимир Стругов, (unknown), (unknown), (unknown), Andrey Zaritskey	8
12	Effect of IGHV Gene Mutation Status and BCR Structure Stereotypy on Effectiveness of BR Regimen in First-Line Therapy of Chronic Lymphocytic Leukemia 2017 ·Clinical oncohematology ·Владимир Стругов, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Andrey Zaritskey	0
13	Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial 2017 ·The Lancet Haematology ·Asher Chanan‐Khan, Andrey Zaritskey, Miklós Egyed, Samuel Vokurka, С. В. Семочкин, Anna Schuh, Jeannine Kassis, David Simpson, Jennie Zhang, (unknown), Robin Foà	29
14	Multicenter prospective escalation-deescalation PET-guided clinical study in classical type Hodgkin disease in the North-West of Russian Federation (RNWOHG-HD1): rationale and design 2017 ·Boris V. Afanasyev, Ivan Moiseev, С. М. Алексеев, (unknown), Elena Kondakova, (unknown), А. М. Belyaev, Andrey Zaritskey, (unknown), (unknown), Sergey Voloshin, В. Моисеенко, (unknown)	3
15	Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia 2016 ·Leukemia & lymphoma ·Anders Österborg, (unknown), Andrey Zaritskey, (unknown), Sebastian Grosicki, Grzegorz Mazur, Polina Kaplan, Michael Steurer, Anna Schuh, Marco Montillo, Iryna Kryachok, Jan Moritz Middeke, Yaroslav Kulyaba, (unknown), M Gorczyca, (unknown), (unknown), Steen Lisby, Ira Gupta	20
16	Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-SCT) with Post-Transplant Cyclophosphamide for haematological malignancies: a single centre experience 2016 ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Vladimir Ivanov, (unknown), Andrey Zaritskey	1
17	Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia 2015 ·Blood ·Elza Lomaia, Andrey Zaritskey, Vasily Shuvaev, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Abdulkadyrov Km	10
18	Bone marrow- and subcutaneous adipose tissue-derived mesenchymal stem cells: Differences and similarities 2012 ·Cell Cycle ·Renata I. Dmitrieva, (unknown), (unknown), (unknown), Sergey V. Anisimov, Andrey Zaritskey	144
19	Successful non‐myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome 2002 ·British Journal of Haematology ·Naoto T. Ueno, Αchilles Anagnostopoulos, Gabriela Rondón, Richard E. Champlin, (unknown), (unknown), (unknown), (unknown), Boris V. Afanasyev, Susan O’Brien, Michael Andreeff, Andrey Zaritskey	52
20	Ultraviolet irradiation induces multiple DNA double‐strand breaks and apoptosis in normal granulocytes and chronic myeloid leukaemia blasts 1997 ·British Journal of Haematology ·Konstantin Bogdanov, (unknown), Andrey Zaritskey, (unknown), B. V. Аfanasiev	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact